Reference is made to the stock exchange announcement published by Nykode
Therapeutics ASA (the "Company") on 25 October 2023 regarding the successful
placing of a private placement of new shares (the "Private Placement") and the
disclosure of shareholding by Datum Opportunity AS and Jan Haudemann-Andersen
resulting from lending of shares in connection with settlement of the Private
Placement. 

The borrowed shares have now been re-delivered following registration of the
share capital increase pertaining to the Private Placement. Datum Opportunity AS
holds a total of 26,000,000 shares, equal to 8.00% of the new share capital of
the Company, and Jan Haudemann-Andersen and companies controlled by him
(including Datum Opportunity AS) holds a total of 41,189,050 shares, equal to
12.67% of the new share capital of the Company.

This announcement is made in accordance with Section 4-2 of the Norwegian
Securities Trading Act.